By Josh Beckerman
Moderna said the first participant has been dosed in a Phase 3 study of mRNA-1083, its combination vaccine candidate against influenza and Covid-19.
The trial is expected to enroll about 8,000 people, age 50 and over.
Earlier in October, the company reported favorable Phase 1/2 data for mRNA-1083, which is now its first respiratory combination vaccine candidate to enter a Phase 3 trial. Moderna said it continues to target a potential initial regulatory approval in 2025.
Moderna reported a $1.38 billion loss in the second quarter as revenue fell to $344 million from $4.75 billion. Last week, Moderna reaffirmed 2023 Covid-19 vaccine sales guidance of $6 billion to $8 billion. It is scheduled to report third-quarter results Nov. 2.
Write to Josh Beckerman at [email protected]
Read the full article here
